Sample Description
Discovery sample: The 7129 discovery cases came from samples we call the CLOZUK (n=6,558) and CardiffCOGS (n=571) series which have in part been described previously (1-3). The CLOZUK sample consists of patients taking clozapine, who provide regular blood samples to allow early detection of adverse effects of that treatment. Through collaboration with Novartis, the manufacturer of a proprietary form of clozapine (Clozaril), we acquired blood from people with schizophrenia who were taking the drug via the central processing labs of a clozapine blood monitoring service. After the samples had been used to complete the necessary laboratory tests, unused fractions were sent to Tepnel Life Sciences (Paisley, UK) for DNA extraction. Samples were anonymous, only basic demographic and diagnostic details being made available. Subjects (71% male) were UK residents, aged 18-90 with a recorded diagnosis of treatment resistant schizophrenia according to the clozapine registration forms completed by the treating psychiatrists. In the UK, treatment resistant schizophrenia implies a lack of satisfactory clinical improvement to adequate trials of at least two other antipsychotics. Approval by the local ethics committee was granted for the use of these samples in genetic association studies.
The CardiffCOGS is a sample of clinically diagnosed schizophrenic patients from the UK.
Interview with the SCAN instrument (4) and case note review was used to arrive at a bestestimate lifetime diagnosis according to DSM-IV criteria (5).
All cases were genotyped on either HumanOmniExpress-12v1 or HumanOmniExpressExome-8v1 arrays at the Broad Institute, Cambridge, Massachusetts.
All controls for the discovery sample were downloaded with the relevant approvals for our study from the online repositories Database of Genotypes and Phenotypes (dbGaP) and the European Genome-Phenome Archive (EGA). The four non-psychiatric control datasets obtained, totalling 12,080 samples, are summarised in Table S1 . We purposefully selected datasets that were genotyped on high density Illumina arrays to maximise probe overlap with the Illumina arrays used to genotype cases. Irish sample: Details of these samples have been published previously (9) . WTCCC2
Dataset
samples that overlapped with our discovery sample were excluded. Calls in the Irish schizophrenia sample were created using Birdseye from Birdsuite (version 1.5.5)(7) for autosomes and we excluded calls where lengths were <100kb or >10Mb, or LOD score <10.
We excluded CNVs with at least 50% overlap with other regional CNVs present in 1% or more of the samples. We excluded individuals with >30 CNV calls, or a total CNV length >10Mbp. Calls from plates containing fewer than 40 samples were also excluded. Genotyping, quality control, and imputation. DNA was extracted from peripheral blood samples at the Karolinska Institutet Biobank. Samples were genotyped in six batches at the Broad Institute using Affymetrix 5.0 (3.9%), Affymetrix 6.0 (38.6%), and Illumina OmniExpress (57.4%) chips according to the manufacturers" protocols. Genotype calling, quality control, and imputation were done in four sets corresponding to data from Affymetrix 5.0 (Sw1), Affymetrix 6.0 (Sw2-4), and the OmniExpress batches (Sw5, Sw6). Genotypes were called using Birdsuite (Affymetrix) or BeadStudio (Illumina). The quality control parameters applied were: SNP missingness < 0.05 (before sample removal); subject missingness < 0.02; autosomal heterozygosity deviation; SNP missingness < 0.02 (after sample removal); difference in SNP missingness between cases and controls < 0.02; and deviation from Hardy-Weinberg equilibrium (P < 10 −6 in controls or P < 10 −10 in cases).
The Birdseye tool in Birdsuite (7) was applied to intensity data from SNP and CNV probes.
The Birdseye algorithm uses a hidden Markov model (HMM) approach to find regions of variable copy number in a sample. Model priors were generated for each genotyping platform. All genomic positions were mapped to the hg19 coordinates.
A multi-step quality control (QC) procedure was implemented in order to assemble a highquality rare CNV callset. Samples were excluded if they failed SNP QC or if they had > 40
CNV calls or > 10Mb of CNVs(8). CNVs were excluded if they were of low confidence (LOD <10, size < 20kb, or spanning < 10 probes) or if they overlapped large genomic gaps (≥1kb overlap). Any CNVs that appeared to be artificially split by the HMM were annealed. Next, we imposed a 1% frequency threshold by removing any CNV with > 50% of its length spanning a region with CNVs from >1% of total samples as implemented in PLINK (24) . After excluding samples which overlapped with the ISC dataset, CNVs were interrogated in 4,655 cases and 6,038 controls.
African American sample:
The Genomic Psychiatry Cohort (GPC) is a clinical cohort of patients enrolled at sites across the United States, in a collaboration directed by Drs.
Michele and Carlos Pato at USC. Psychiatric diagnoses were made through personal interviews and review of the medical records. Interviews were performed by trained clinicians using a structured psychiatric interview instrument, the Diagnostic Interview for Psychosis and Affective Disorder (DI-PAD), to assess participants. The DI-PAD is based on the Diagnostic Interview for Genetic Studies (DIGS) and includes 90 phenomenological symptom items that are used to arrive at final diagnoses under various diagnostic criteria.
Clinicians reviewed diagnoses that were based on DSM-IV (5). Cases were included in the current study if they met criteria for schizophrenia or schizoaffective disorder. Individuals without a personal or family history of psychosis or mania were eligible to participate as controls. In the current study, we genotyped samples from the GPC cohort members with self-reported African American ancestry. Controls were asked to complete a questionnaire to assess their psychiatric history and the psychiatric history of all first-degree relatives.
Individuals reporting any lifetime symptoms indicative of psychosis or mania were excluded as control participants
CNVs were called on all samples using PennCNV and NCBI37/hg19 coordinates. The following samples were removed: duplicate individuals, first degree relatives (if discordant phenotypes, always the control was removed), individuals with more than 2% missing genotypes, individuals with more than 60% European ancestry, individuals with more than 10Mbp of the genome estimated as CNV. After quality control, CNVs were analysed in 1,637 cases and 960 controls.
Discovery sample quality control
Raw intensity data from each case/control dataset were independently processed and analysed to account for potential batch effects. Log R ratios (LRR) and B-allele frequencies were generated using Illumina Genome Studio software (v2011.1). CNVs were called using the PennCNV calling algorithm, following the standard protocol and adjusting for GC content.
CNVs were called using the 520,766 probes common to all discovery arrays to avoid a cross-platform CNV locus detection bias. Samples were excluded if for any one of the following QC metrics they represented an outlier in their source dataset: LRR standard deviation, B-allele frequency drift, wave factor and total number of CNVs called per person. Table S2 shows the number of samples that passed and failed QC from each discovery dataset. As some of the data had been already filtered for quality before they were downloaded, the proportions of failed samples across the datasets are not comparable. Following the exclusion of poorly performing samples, we performed quality control on the called CNVs. Firstly, CNVs in the same individual were joined if the distance separating them was less than 50% of their combined length using a custom developed open source programme (http://x004.psycm.uwcm.ac.uk/~dobril/combine_CNVs/). All CNVs were then excluded if they were covered by less than 10 probes, were less than 10kb in length, overlapped with low copy repeats by more than 50% of their length, or had a probe density (calculated by dividing the size of the CNV by the number of probes covering it) greater than 1 probe/20kb. CNV loci with a frequency > 1% of the total discovery sample were excluded using PLINK (24).
Sample
The remaining rare CNVs were required to pass a median Z-score outlier method of validation. This method is detailed in Kirov et al, 2012 (25) and Rees et al (3) . Briefly, each probe intensity within an individual is converted to a Z-score, which is the probe intensity standardised across all probes within that individual, and then standardised for that probe across all individuals. These rounds of standardisation help reduce noise created by natural fluctuations in probe intensity. A median Z-score value for all probes within a putative CNV region is used to assess copy number, with true deletions and duplications represented as outliers in the samples median Z-score distribution. Each CNV in every individual was assigned a Z-score. CNVs with Z-scores of <-6 were accepted as true deletions, while those with Z-sores of >+3 were accepted as duplications. The Z-score histograms of CNVs with marginal Z-Scores (deletion Z-score between -4 and -6 and duplication Z-score between +2 and +3) were manually inspected, and from these CNVs the LRR and B-allele frequencies of those with ambiguous Z-scores were visually inspected with the Illumina GenomeStudio v2011.1 software. This resulted in 2,569 CNVs being filtered out from the data.
Previously implicated CNV regions.
To identify novel CNV associations, we excluded from our analysis regions previously implicated in schizophrenia. These regions, along with the number of CNVs observed in our discovery sample, are presented in Table S3 . Some or all of the 4,939 WTCCC2 control samples have been included in previous reviews, or in papers that implicated these loci, so the numbers for the control populations are not entirely independent from previous reports.
The evidence that these loci are implicated in SZ is presented in Rees et al (3) . Table S3 is based on the data presented in that publication, but not identical to it, as here we include the WTCCC2 controls, that were not used in Rees et al (3) . We present the full data here only in order to demonstrate the power of the current sample to detect real associations. Table S4 . Burden of large CNVs before and after removing implicated loci. CNVs are stratified by type (all, deletions only, duplications only) and size (500kb -1Mb and > 1Mb).
CNV burden analysis
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Location of CNVs that remained significant with a combined discovery/replication CochranMantel-Haenszel test (Table 1 in 
